A multicenter randomized study comparing 6 versus 12 months of trastuzumab in combination with dose-dense docetaxel following FEC as adjuvant treatment of women with axillary-node–positive or high-risk, node-negative breast cancer overexpressing HER2.

Authors

Dimitrios Mavroudis

Hellenic Oncology Research Group (HORG), Athens, Greece

Dimitrios Mavroudis , Nikolaos A. Malamos , Stylianos Kakolyris , Ioannis Boukovinas , Pavlos Papakotoulas , Nikolaos Ziras , Vassilis Georgoulias

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial.

First Author: Begoña Bermejo

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

First Author: Theodoros Foukakis

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).

First Author: Esther Pohl-Rescigno

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).

First Author: Wolfgang Janni